CMA CPA - Mednow Chief Officer
| MDNWF Stock | USD 0.02 0.00 0.00% |
Insider
CMA CPA is Chief Officer of Mednow Inc
| Phone | 855-686-6300 |
| Web | https://www.mednow.ca |
Mednow Management Efficiency
The company has return on total asset (ROA) of (0.5537) % which means that it has lost $0.5537 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.897) %, meaning that it generated substantial loss on money invested by shareholders. Mednow's management efficiency ratios could be used to measure how well Mednow manages its routine affairs as well as how well it operates its assets and liabilities.Mednow Inc has accumulated 30 K in total debt with debt to equity ratio (D/E) of 0.28, which may suggest the company is not taking enough advantage from borrowing. Mednow Inc has a current ratio of 1.79, which is within standard range for the sector. Debt can assist Mednow until it has trouble settling it off, either with new capital or with free cash flow. So, Mednow's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mednow Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mednow to invest in growth at high rates of return. When we think about Mednow's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Liean MS | Acumen Pharmaceuticals | N/A | |
| MinHwan Kao | Garmin | 76 | |
| Cammeron McLaughlin | Sonos Inc | N/A | |
| Eli Yaffe | Eltek | 70 | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Maxime BouvatMerlin | Sonos Inc | 49 | |
| Philip Straub | Garmin | 54 | |
| Russell MS | Acumen Pharmaceuticals | 67 | |
| Catherine Lewis | Garmin | 68 | |
| Sean Biddlecombe | Garmin | N/A | |
| Thomas Cullen | Sonos Inc | N/A | |
| Ted Gartner | Garmin | N/A | |
| Siew MS | Acumen Pharmaceuticals | N/A | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| Jonathan Burrell | Garmin | 56 | |
| Ruth Sleeter | Sonos Inc | N/A | |
Management Performance
| Return On Equity | -1.9 | |||
| Return On Asset | -0.55 |
Mednow Inc Leadership Team
Elected by the shareholders, the Mednow's board of directors comprises two types of representatives: Mednow inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mednow. The board's role is to monitor Mednow's management team and ensure that shareholders' interests are well served. Mednow's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mednow's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CMA CPA, Chief Officer | ||
| Felipe RPh, Treasurer, CoFounder | ||
| Simranveer Grewal, VP Technology | ||
| Amir RPh, CEO CoFounder | ||
| Anthony Perlman, VP Strategy | ||
| Dave Marantz, Chief Officer | ||
| Lindsay Nahmiache, Member Advisor |
Mednow Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Mednow a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.9 | |||
| Return On Asset | -0.55 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (0.82) % | |||
| Current Valuation | 4.96 M | |||
| Shares Outstanding | 21.57 M | |||
| Shares Owned By Insiders | 47.93 % | |||
| Price To Book | 0.97 X | |||
| Price To Sales | 0.18 X | |||
| Revenue | 16.64 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Mednow Pink Sheet
Mednow financial ratios help investors to determine whether Mednow Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mednow with respect to the benefits of owning Mednow security.